Webinars and Webcasts of Interest for Parkinson's Disease

For PwPs, Caregivers and Families:
You might be like to attend these online events

Drug Development Pipeline on Thursday, June 24th, 2010

2:00 pm to 4:30 pm EST

Direct from the Campus of Georgetown University, Parkinson's Action Network (PAN) is hosting "Emerging Therapies: From Microscope to Marketplace" featuring a panel of speakers from the scientific community. Each will address a different stage in the drug development pipeline process.

Howard Federoff, M.D., Ph.D.: Executive Vice President for Health Sciences and Executive Dean of the School of Medicine at Georgetown University will moderate.

The panel:

James P. Bennett, Jr., M.D., Ph.D.: Chair, Department of Neurology and Founding Director of the Virginia Commonwealth University Parkinson's Disease and Movement Disorders Multidisciplinary Research and Clinical Center

Story C. Landis, Ph.D.: Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health

Raymond T. Bartus, Ph.D.: Executive Vice President and Chief Scientific Officer, Ceregene, Inc.

Jackie Hunt Christensen: PAN Minnesota State Coordinator and Clinical Trial Participant

Janet Woodcock, M.D.: Director, Center for Drug Evaluation and Research, Food and Drug Administration

Registration is not required. On the day of the Webcast, simply visit the PAN home page and tune into the Webcast from your home or office computer.
For more information on the Webcast, please e-mail PAN

Registration is not required. On the day of the Webcast, simply visit the PAN home page and tune into the Webcast from your home or office computer.

~~~~~~~~~~~~~~~~~~~~~~~~

From AARP on the same day, Thursday, June 24, 2010

"The New Health Care Law: What It Means for People with Medicare"

Times are:

2:00pm -3:00pm EST

1:00-2:00 pm CST

12:00 pm-1:00 pm MST

11:00 am -12:00 pm PST

To register at AARP for this event, click here

There will be a Question and Answer period with AARP experts

~~~~~~~~~~~~~~~~~~~~

Did you miss one of the Parkinson's Disease Foundation (PDF) Educational Events?

You can see and/or hear them here.

Parkinson's Disease Community Input for Stem Cell Federal Support Guidelines Needed

It's time to be counted: Your PD-related Input is Needed for the Federal Funding Guidelines for Embryonic Stem Cell Research (ESCR)

We received the email below from the Parkinson's Action Network (PAN) as did many of you. We are reprinting that email as a reminder that there is still work to be done to be done by all of us. It's as simple as a CLICK on the comment submission form link and a CUT and PASTE of selected paragraphs below... although you may want to edit some of the wording which you can do easily after the paste.

Communication from PAN:

Help Ensure Strong Federal Support for Stem Cell Research Submit Comments on NIH Draft Stem Cell Guidelines

Deadline May 26th!
On March 9th, President Obama issued an Executive Order lifting the past administration’s restrictive policy on embryonic stem cell research (ESCR) and instructing the National Institutes of Health(NIH) to develop guidelines for federal funding of ESCR. NIH has released its draft guidelines and the public has been given the opportunity to submit comments. NIH will review the content and volume of comments as it drafts its final framework for federal funding of ESCR.

It is critical that we show our support for this important research. Please help generate as many comments as possible between now and the May 26th filing deadline. Each comment will be recorded and counted!

The Executive Order was a major step forward, but as with many complex issues, there are details of the draft guidelines that should be changed and/or clarified to ensure the framework created builds on current progress. The Parkinson’s community has been a leader in the fight for an ethical framework for ESCR—please continue your advocacy efforts by helping us ensure the final guidelines allow for this important science to advance as quickly as possible. To read a summary of the draft guidelines, click here.

Submit your comments using the instructions below and encourage your family, friends, and community to submit comments.

How to Submit Your Comments:
To access the NIH comment form, visit:
http://nihoerextra.nih.gov/stem_cells/add.htm
Provide your name, and select ‘self’ for Affiliation;
Copy and paste the text below into the comment box,
Edit as appropriate,
Provide the security check ID on the form,
and click ‘Submit Comments.’

Suggested Comment Text: Embryonic stem cell research holds great promise for millions of Americans suffering from many diseases and disorders. I am not a scientist, but I am a member of the Parkinson’s community and have been following progress in this field with great interest. Significant strides have been made over the past decade, and the final guidelines issued by NIH must build on this progress so that cures and new therapies can get to patients as quickly as possible. The final guidelines should not create new bureaucratic hurdles that will slow the pace of progress.

I am pleased that these draft guidelines -- in Section II B -- would appear to permit federal funding of stem cell lines previously not eligible for federal funding and for new lines created in the future from surplus embryos at fertility clinics. However, as drafted, Section II B does not ensure that any current stem cell line will meet the criteria outlined and thus be eligible for federal funding. It will be important for the final guidelines to allow federal funds for research using all stem cell lines created by following ethical practices at the time they were derived. This will ensure that the final guidelines build on progress that has already been made.

I also believe that the final guidelines should permit federal funding for stem cell lines derived from sources other than excess IVF embryos, such as somatic cell nuclear transfer (SCNT). Sections II Band IV of the draft guidelines do not permit such federal funding and I recommend that the final guidelines provide federal funding using stem cell lines derived in other ways. If not, it is essential that the NIH continue to monitor developments in this exciting research area and to update these guidelines as the research progresses.

To learn more about human embryonic stem cell research, please visit the Coalition for the Advancement of Medical Research at
http://www.camradvocacy.org/